Bioinformatics: A Vital Precursor To Successful Biomanufacturing

By Arghya Barman, Associate Director Global Data Science, FUJIFILM Diosynth Biotechnologies, UK

Monoclonal antibodies (mAbs) and novel antibodies can display good specificity and affinity for their targets, but their physical and chemical instability can have a detrimental impact on their capacity to be manufactured effectively. Post-translational modifications and charge heterogeneity enhance the possibility of immunogenicity, while aggregation decreases protein function and increases concerns about an immune response.

The ability to identify liabilities of a molecule is extremely important for process, analytical method, and formulation development. At FUJIFILM Diosynth Biotechnologies (FDB), we understand the importance of de-risking candidate selection, accelerating time to clinic and that bioinformatics can play a pivotal role, so we start these conversations with our clients from the very outset.

In this article, review FDB's approach to bioinformatics and how in silico manufacturability assessment factors were applied to four candidate mAbs.